Omnipod 5

HCP with child and mother in an exam room
RADIANT Trial: Omnipod® 5 Demonstrates Superior Glycemic Results vs Multiple Daily Injections

Automated insulin delivery (AID) has increasingly become the standard of care for people with type 1 diabetes, driven by strong evidence of improved glycemic results.

Brenda Ferris, MS, RD, CDCES, CDN *
HCP with young podder patient and parent
Switching Patients from Other Automated Insulin Delivery (AID) Systems to Omnipod® 5
Guest Blogger
HCP and patient sitting at a desk in an office talking
Omnipod® 5 Shows Significant Improvements in Glycemic Measures and Diabetes Distress

Omnipod 5 is the first automated insulin delivery system (AID) FDA cleared for patients with type 2 diabetes in the US. It is also the first and only tubeless AID system in the US. A single arm, multicenter prospective study by Pasquel et al.

Brenda Ferris, MS, RD, CDCES, CDN *
HCP non-clinical setting
Real-World Evidence of Omnipod® 5 Shows Glycemic Outcomes That Indicate Effective Use of the System in a Non-Clinical Setting

In February of 2024, Forlenza et al.

Guest Blogger
Omnipod 5 How-to Video Activity Feature
Optimizing the Omnipod® 5 Activity Feature for Your Patients
Guest Blogger
HCP man on laptop
Pivotal Study Shows Omnipod® 5 Improved Glycemic Measures for Patients with Type 1 Diabetes
Brenda Ferris, MS, RD, CDCES, CDN *
HCP with podder paitient in yellow dress
Switching Patients from Multiple Daily Injections (MDI) to Omnipod® 5
Guest Blogger